LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based RegimenAt five years, LENVIMA plus KEYTRUDA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the pivotal Phase 3 Study 309/KEYNOTE-775 trial

Five-year OS results in the pMMR subgroup were consistent with the all-comers study population, which demonstrated an OS rate of 19.9% for LENVIMA plus KEYTRUDA versus 7.7% for chemotherapy